Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedA reference to a 2012 NEJM article on PD-L1 was removed from the page’s references.SummaryDifference0.1%

- Check9 days agoChange DetectedDeleted the bibliographic reference 'Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.' from the page. This removal does not alter the study design, endpoints, or other critical trial details.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.4.2 was added and the older funding-status notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check30 days agoChange DetectedAdded a site-wide notice about funding status and operations and updated the page version from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check37 days agoChange DetectedAdded a 'Show glossary' option and updated footer notes to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while removing the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check44 days agoChange DetectedA reference to the 1994 NEJM randomized trial on preoperative chemotherapy plus surgery versus surgery alone in NSCLC was added to the page.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.